|
|
LIVE WEBINAR: Wednesday, March 18, 2026 | 5:00 PM – 6:00 PM Eastern Time (ET)
What Clinicians Want to Know: First-Line and Maintenance Therapy for Patients with ER-Positive, HER2-Positive Metastatic Breast CancerA CME/MOC-Accredited Live WebinarJoin us on Wednesday, March 18th for this CME/MOC-accredited webinar Faculty
Virginia F Borges, MD, MMSc Professor of Medicine with Tenure Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research Deputy Head, Division of Medical Oncology Director, Breast Cancer Research Program and Young Women’s Breast Cancer Translational Program University of Colorado Cancer Center Aurora, Colorado Ian E Krop, MD, PhD Professor of Internal Medicine Associate Cancer Center Director for Clinical Research Yale Cancer Center New Haven, Connecticut
Moderator
Neil Love, MD Research To Practice Miami, Florida Wednesday, March 18, 2026 Topics to be announced. Target Audience Learning Objectives CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Privacy Policy Unlabeled/Unapproved Uses Notice Content Validation and Disclosures FACULTY
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |